25 XP   0   0   10

Aptevo Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Aptevo Therapeutics Inc together

PenkeI guess you are interested in Aptevo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aptevo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aptevo Therapeutics Inc

I send you an email if I find something interesting about Aptevo Therapeutics Inc.

Quick analysis of Aptevo Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Aptevo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.01
When do you have the money?
1 year
How often do you get paid?
5.4%

What is your share worth?

Current worth
$18.15
Expected worth in 1 year
$9.60
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
$-8.53
Return On Investment
-1,254.6%

For what price can you sell your share?

Current Price per Share
$0.68
Expected price per share
$0 - $7.48
How sure are you?
50%

1. Valuation of Aptevo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.68

Intrinsic Value Per Share

$-383.37 - $-456.92

Total Value Per Share

$-365.22 - $-438.77

2. Growth of Aptevo Therapeutics Inc (5 min.)




Is Aptevo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$12.2m$12.7m$3.8m23.4%

How much money is Aptevo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.1m$19m-$21.2m-967.9%
Net Profit Margin0.0%-323.6%--

How much money comes from the company's main activities?

3. Financial Health of Aptevo Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#652 / 1010

Most Revenue
#865 / 1010

Most Profit
#312 / 1010

Most Efficient
#317 / 1010

What can you expect buying and holding a share of Aptevo Therapeutics Inc? (5 min.)

Welcome investor! Aptevo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aptevo Therapeutics Inc.

What can you expect buying and holding a share of Aptevo Therapeutics Inc?

First you should know what it really means to hold a share of Aptevo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aptevo Therapeutics Inc is $0.68. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aptevo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aptevo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $18.15. Based on the TTM, the Book Value Change Per Share is $-2.14 per quarter. Based on the YOY, the Book Value Change Per Share is $6.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aptevo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-8.77-1,289.1%-10.44-1,535.9%-1.09-160.9%-3.68-541.1%-8.60-1,264.2%
Usd Book Value Change Per Share-3.71-545.3%-2.14-314.1%6.61972.1%0.1419.9%0.4972.1%
Usd Dividend Per Share0.000.0%0.000.4%0.000.0%0.1015.0%0.058.1%
Usd Total Gains Per Share-3.71-545.3%-2.13-313.6%6.61972.1%0.2434.9%0.5580.2%
Usd Price Per Share0.18-1.00-3.70-7.72-4.99-
Price to Earnings Ratio-0.01--0.02--0.34--1.02--0.56-
Price-to-Total Gains Ratio-0.05--0.02--1.35-0.62-0.33-
Price to Book Ratio0.01-0.04--0.77-4.23-2.31-
Price-to-Total Gains Ratio-0.05--0.02--1.35-0.62-0.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.68
Number of shares1470
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.10
Usd Book Value Change Per Share-2.140.14
Usd Total Gains Per Share-2.130.24
Gains per Quarter (1470 shares)-3,135.13348.45
Gains per Year (1470 shares)-12,540.501,393.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
117-12558-125515987961384
235-25116-25092119615912778
352-37674-37633179523874172
470-50232-50174239331825566
587-62790-62715299139786960
6105-75348-75256358947738354
7122-87906-87797418855699748
8140-100464-1003384786636511142
9157-113022-1128795384716012536
10175-125580-1254205982795613930

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%4.033.00.010.8%4.033.00.010.8%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%11.024.02.029.7%11.024.02.029.7%
Dividend per Share1.00.03.025.0%2.00.010.016.7%2.00.018.010.0%2.00.035.05.4%2.00.035.05.4%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%8.012.00.040.0%12.023.02.032.4%12.023.02.032.4%

Fundamentals of Aptevo Therapeutics Inc

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2024-04-11 00:52:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Aptevo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aptevo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-323.6%+323.6%
TTM-5Y-246.7%+246.7%
5Y-246.7%10Y-214.8%-31.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY-323.6%-282.3%-41.3%
5Y-246.7%-436.8%+190.1%
10Y-214.8%-597.3%+382.5%
1.1.2. Return on Assets

Shows how efficient Aptevo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • -23.8% Return on Assets means that Aptevo Therapeutics Inc generated $-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aptevo Therapeutics Inc:

  • The MRQ is -23.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.8%TTM-10.5%-13.3%
TTM-10.5%YOY51.5%-62.0%
TTM-10.5%5Y0.1%-10.6%
5Y0.1%10Y-7.2%+7.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.8%-13.3%-10.5%
TTM-10.5%-12.8%+2.3%
YOY51.5%-11.6%+63.1%
5Y0.1%-13.8%+13.9%
10Y-7.2%-15.6%+8.4%
1.1.3. Return on Equity

Shows how efficient Aptevo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • -48.3% Return on Equity means Aptevo Therapeutics Inc generated $-0.48 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aptevo Therapeutics Inc:

  • The MRQ is -48.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-48.3%TTM-22.8%-25.5%
TTM-22.8%YOY98.9%-121.7%
TTM-22.8%5Y-51.5%+28.7%
5Y-51.5%10Y-38.9%-12.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.3%-16.9%-31.4%
TTM-22.8%-16.1%-6.7%
YOY98.9%-14.9%+113.8%
5Y-51.5%-19.3%-32.2%
10Y-38.9%-20.1%-18.8%

1.2. Operating Efficiency of Aptevo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aptevo Therapeutics Inc is operating .

  • Measures how much profit Aptevo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY16.6%-16.6%
TTM-5Y-171.0%+171.0%
5Y-171.0%10Y-163.7%-7.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY16.6%-288.4%+305.0%
5Y-171.0%-486.2%+315.2%
10Y-163.7%-628.4%+464.7%
1.2.2. Operating Ratio

Measures how efficient Aptevo Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.071-0.071
TTM-5Y2.353-2.353
5Y2.35310Y2.717-0.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY0.0713.838-3.767
5Y2.3535.679-3.326
10Y2.7177.823-5.106

1.3. Liquidity of Aptevo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.64 means the company has $2.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 2.639. The company is able to pay all its short-term debts. +1
  • The TTM is 3.481. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.639TTM3.481-0.842
TTM3.481YOY3.136+0.345
TTM3.4815Y2.632+0.850
5Y2.63210Y2.969-0.337
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6393.863-1.224
TTM3.4814.169-0.688
YOY3.1365.337-2.201
5Y2.6326.122-3.490
10Y2.9696.434-3.465
1.3.2. Quick Ratio

Measures if Aptevo Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.34 means the company can pay off $2.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 2.340. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.136. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.340TTM3.136-0.796
TTM3.136YOY2.883+0.253
TTM3.1365Y2.344+0.792
5Y2.34410Y3.034-0.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3403.504-1.164
TTM3.1363.991-0.855
YOY2.8835.371-2.488
5Y2.3446.088-3.744
10Y3.0346.395-3.361

1.4. Solvency of Aptevo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aptevo Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aptevo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.51 means that Aptevo Therapeutics Inc assets are financed with 50.8% credit (debt) and the remaining percentage (100% - 50.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 0.508. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.435. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.508TTM0.435+0.073
TTM0.435YOY0.628-0.194
TTM0.4355Y0.645-0.211
5Y0.64510Y0.492+0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5080.339+0.169
TTM0.4350.337+0.098
YOY0.6280.271+0.357
5Y0.6450.368+0.277
10Y0.4920.388+0.104
1.4.2. Debt to Equity Ratio

Measures if Aptevo Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 103.3% means that company has $1.03 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aptevo Therapeutics Inc:

  • The MRQ is 1.033. The company is able to pay all its debts with equity. +1
  • The TTM is 0.790. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.033TTM0.790+0.243
TTM0.790YOY0.649+0.140
TTM0.7905Y4.848-4.059
5Y4.84810Y2.847+2.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0330.392+0.641
TTM0.7900.403+0.387
YOY0.6490.335+0.314
5Y4.8480.427+4.421
10Y2.8470.461+2.386

2. Market Valuation of Aptevo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aptevo Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Aptevo Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.01 means the investor is paying $-0.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -0.019. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.005. Based on the earnings, the company is expensive. -2
  • The TTM is -0.022. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.019MRQ-0.005-0.014
MRQ-0.005TTM-0.022+0.017
TTM-0.022YOY-0.343+0.321
TTM-0.0225Y-1.018+0.996
5Y-1.01810Y-0.555-0.462
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.019-2.300+2.281
MRQ-0.005-2.656+2.651
TTM-0.022-2.718+2.696
YOY-0.343-4.145+3.802
5Y-1.018-6.258+5.240
10Y-0.555-6.315+5.760
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is -0.022. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.002. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-0.022MRQ-0.006-0.016
MRQ-0.006TTM0.002-0.008
TTM0.002YOY-0.874+0.876
TTM0.0025Y-1.393+1.395
5Y-1.39310Y-1.073-0.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.022-2.974+2.952
MRQ-0.006-3.306+3.300
TTM0.002-3.508+3.510
YOY-0.874-5.613+4.739
5Y-1.393-8.378+6.985
10Y-1.073-8.873+7.800
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aptevo Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.01 means the investor is paying $0.01 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aptevo Therapeutics Inc:

  • The EOD is 0.037. Based on the equity, the company is cheap. +2
  • The MRQ is 0.010. Based on the equity, the company is cheap. +2
  • The TTM is 0.036. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.037MRQ0.010+0.027
MRQ0.010TTM0.036-0.026
TTM0.036YOY-0.769+0.805
TTM0.0365Y4.226-4.190
5Y4.22610Y2.307+1.919
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0371.914-1.877
MRQ0.0102.116-2.106
TTM0.0362.097-2.061
YOY-0.7692.881-3.650
5Y4.2263.550+0.676
10Y2.3073.936-1.629
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aptevo Therapeutics Inc.

3.1. Institutions holding Aptevo Therapeutics Inc

Institutions are holding 8.297% of the shares of Aptevo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Renaissance Technologies Corp1.74410.0002516789340809193.6635
2023-12-31Sabby Management LLC1.17940.0632349471-984698-73.8061
2023-09-30Schonfeld Strategic Advisors LLC0.48190.0004142800-1800-1.2448
2023-12-31Squarepoint Ops LLC0.46810.00011386971386970
2023-12-31Millennium Management LLC0.35301046081046080
2023-12-31Vanguard Group Inc0.3096091725-129339-58.5075
2023-12-31Armistice Capital, LLC0.20630.000261130-1173870-95.0502
2023-12-31BlackRock Inc0.1574046635-1033-2.1671
2023-12-31Geode Capital Management, LLC0.1458043201-32154-42.67
2023-12-31Baader Bank INC0.05090.000215086150860
2023-12-31Northern Trust Corp0.047701412100
2023-12-31Tower Research Capital LLC0.04610136601651.2227
2023-12-31Morgan Stanley - Brokerage Accounts0.03840113703573.2416
2023-12-31TWO SIGMA SECURITIES, LLC0.038011248112480
2023-12-31Franklin Resources Inc0.037101099700
2023-12-31State Street Corporation0.036901094100
2023-12-31DIVERGENT WEALTH ADVISORS, LLC0.03370.00041000000
2023-12-31JPMorgan Chase & Co0.006401897-10-0.5244
2023-12-31Wells Fargo & Co0.005501617553.5211
2023-12-31Fifth Third Bancorp0.001029100
Total 5.38730.06471596284-1711879-107.2%

3.2. Funds holding Aptevo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.410709172500
2024-01-31Fidelity Extended Market Index0.107802407500
2023-06-30CIMA Global Value SICAV0.06270.099514001440.3153
2023-12-31Franklin U.S. Small Cap Equity I0.04610.0021028800
2024-01-31Fidelity Nasdaq Composite Index0.03370752400
2023-09-30BlackRock Extended Mkt Composite0.03320742600
2023-12-31BlackRock Extended Equity Market K0.02906479-13-0.2002
2024-01-31Fidelity Total Market Index0.02660594300
2024-01-31Fidelity Series Total Market Index0.0190423500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.01570349700
2023-12-31NT Quality Small Cap Core0.01550.0003345800
2023-12-31NT Quality SCC US Fund - L0.01550.0003345800
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01260280950.1783
2024-01-31Spartan Total Market Index Pool E0.00640142400
2023-12-31Extended Equity Market Fund M0.00360801384.9803
2023-12-31SSgA U.S. Extended Market Index Class I0.0033073800
2024-02-29State St US Extended Mkt Indx NL Cl C0.0033073800
2024-01-31SAST SA Franklin Tactical Oppos Port 10.00320.000170900
2023-12-31NT US Market Cap Idx Fd - L0.0021047300
2023-12-31Northern Trust Wilshire 50000.0021047300
Total 0.85210.1022190274+74+0.0%

3.3. Insider Transactions

Insiders are holding 0.765% of the shares of Aptevo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-11-22Kevin C TangSELL5802309.32
2021-11-18Kevin C TangSELL8398366.96

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aptevo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.708-2.136-42%6.610-156%0.135-2840%0.490-856%
Book Value Per Share--18.14724.668-26%8.296+119%9.676+88%26.844-32%
Current Ratio--2.6393.481-24%3.136-16%2.632+0%2.969-11%
Debt To Asset Ratio--0.5080.435+17%0.628-19%0.645-21%0.492+3%
Debt To Equity Ratio--1.0330.790+31%0.649+59%4.848-79%2.847-64%
Dividend Per Share---0.003-100%-0%0.102-100%0.055-100%
Eps---8.766-10.444+19%-1.094-88%-3.680-58%-8.597-2%
Free Cash Flow Per Share---7.800-4.355-44%-2.966-62%-3.019-61%-6.319-19%
Free Cash Flow To Equity Per Share---3.277-2.128-35%-1.172-64%-0.603-82%1.224-368%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---456.922--------
Intrinsic Value_10Y_min---383.365--------
Intrinsic Value_1Y_max---16.376--------
Intrinsic Value_1Y_min---16.068--------
Intrinsic Value_3Y_max---71.618--------
Intrinsic Value_3Y_min---67.920--------
Intrinsic Value_5Y_max---153.884--------
Intrinsic Value_5Y_min---140.902--------
Market Cap457932.400+73%121890.830674440.145-82%16001028.295-99%32562360.758-100%18889264.431-99%
Net Profit Margin----0%-3.2360%-2.4670%-2.1480%
Operating Margin----0%0.166-100%-1.7100%-1.6370%
Operating Ratio----0%0.071-100%2.353-100%2.717-100%
Pb Ratio0.037+73%0.0100.036-72%-0.769+7812%4.226-100%2.307-100%
Pe Ratio-0.019-276%-0.005-0.022+326%-0.343+6540%-1.018+19615%-0.555+10659%
Price Per Share0.680+73%0.1811.002-82%3.703-95%7.720-98%4.991-96%
Price To Free Cash Flow Ratio-0.022-276%-0.0060.002-354%-0.874+14961%-1.393+23909%-1.073+18391%
Price To Total Gains Ratio-0.183-276%-0.049-0.019-62%-1.349+2663%0.624-108%0.333-115%
Quick Ratio--2.3403.136-25%2.883-19%2.3440%3.034-23%
Return On Assets---0.238-0.105-56%0.515-146%0.001-24366%-0.072-70%
Return On Equity---0.483-0.228-53%0.989-149%-0.515+7%-0.389-19%
Total Gains Per Share---3.708-2.133-42%6.610-156%0.237-1664%0.545-780%
Usd Book Value--12221000.00016612000.000-26%12724750.000-4%14487700.000-16%42465243.243-71%
Usd Book Value Change Per Share---3.708-2.136-42%6.610-156%0.135-2840%0.490-856%
Usd Book Value Per Share--18.14724.668-26%8.296+119%9.676+88%26.844-32%
Usd Dividend Per Share---0.003-100%-0%0.102-100%0.055-100%
Usd Eps---8.766-10.444+19%-1.094-88%-3.680-58%-8.597-2%
Usd Free Cash Flow---5253000.000-2932500.000-44%-5269000.000+0%-6357000.000+21%-9734324.324+85%
Usd Free Cash Flow Per Share---7.800-4.355-44%-2.966-62%-3.019-61%-6.319-19%
Usd Free Cash Flow To Equity Per Share---3.277-2.128-35%-1.172-64%-0.603-82%1.224-368%
Usd Market Cap457932.400+73%121890.830674440.145-82%16001028.295-99%32562360.758-100%18889264.431-99%
Usd Price Per Share0.680+73%0.1811.002-82%3.703-95%7.720-98%4.991-96%
Usd Profit---5903000.000-2193750.000-63%19038750.000-131%-963750.000-84%-7777702.703+32%
Usd Revenue----0%-0%2902800.000-100%6052756.757-100%
Usd Total Gains Per Share---3.708-2.133-42%6.610-156%0.237-1664%0.545-780%
 EOD+5 -3MRQTTM+5 -26YOY+7 -245Y+10 -2310Y+6 -27

4.2. Fundamental Score

Let's check the fundamental score of Aptevo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.019
Price to Book Ratio (EOD)Between0-10.037
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.340
Current Ratio (MRQ)Greater than12.639
Debt to Asset Ratio (MRQ)Less than10.508
Debt to Equity Ratio (MRQ)Less than11.033
Return on Equity (MRQ)Greater than0.15-0.483
Return on Assets (MRQ)Greater than0.05-0.238
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Aptevo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.737
Ma 20Greater thanMa 502.077
Ma 50Greater thanMa 1004.225
Ma 100Greater thanMa 2005.854
OpenGreater thanClose0.680
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets24,842
Total Liabilities12,621
Total Stockholder Equity12,221
 As reported
Total Liabilities 12,621
Total Stockholder Equity+ 12,221
Total Assets = 24,842

Assets

Total Assets24,842
Total Current Assets19,066
Long-term Assets5,776
Total Current Assets
Cash And Cash Equivalents 16,904
Other Current Assets 2,162
Total Current Assets  (as reported)19,066
Total Current Assets  (calculated)19,066
+/-0
Long-term Assets
Property Plant Equipment 5,776
Long-term Assets  (as reported)5,776
Long-term Assets  (calculated)5,776
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,224
Long-term Liabilities5,397
Total Stockholder Equity12,221
Total Current Liabilities
Accounts payable 3,984
Other Current Liabilities 3,240
Total Current Liabilities  (as reported)7,224
Total Current Liabilities  (calculated)7,224
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt5,397
Long-term Liabilities  (as reported)5,397
Long-term Liabilities  (calculated)5,397
+/-0
Total Stockholder Equity
Common Stock61
Retained Earnings -223,447
Other Stockholders Equity 235,607
Total Stockholder Equity (as reported)12,221
Total Stockholder Equity (calculated)12,221
+/-0
Other
Capital Stock61
Cash and Short Term Investments 16,904
Common Stock Shares Outstanding 442
Liabilities and Stockholders Equity 24,842
Net Debt -11,507
Net Invested Capital 12,221
Net Working Capital 11,842
Property Plant and Equipment Gross 19,369
Short Long Term Debt Total 5,397



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
119,971
0
0
0
112,456
141,589
118,159
100,623
91,858
97,793
86,891
131,022
117,007
100,212
89,997
78,934
67,494
80,841
66,127
60,556
53,408
25,244
18,509
37,420
53,547
68,753
71,474
64,005
56,601
45,184
38,799
31,695
34,215
34,969
28,912
27,129
24,842
24,84227,12928,91234,96934,21531,69538,79945,18456,60164,00571,47468,75353,54737,42018,50925,24453,40860,55666,12780,84167,49478,93489,997100,212117,007131,02286,89197,79391,858100,623118,159141,589112,456000119,971
   > Total Current Assets 
41,551
0
0
0
35,134
64,407
39,847
79,429
71,414
77,396
67,193
115,322
95,084
77,160
66,247
60,395
48,689
57,642
43,672
36,789
29,995
14,825
10,488
30,653
47,264
62,850
65,765
58,873
52,570
41,672
31,400
24,618
27,450
28,485
22,680
21,126
19,066
19,06621,12622,68028,48527,45024,61831,40041,67252,57058,87365,76562,85047,26430,65310,48814,82529,99536,78943,67257,64248,68960,39566,24777,16095,084115,32267,19377,39671,41479,42939,84764,40735,13400041,551
       Cash And Cash Equivalents 
3,593
0
0
0
4,637
45,000
5,496
10,894
9,676
14,014
22,269
75,830
7,095
11,830
7,228
28,447
30,635
37,011
20,957
17,683
12,448
12,258
7,599
24,942
39,979
57,524
60,394
52,118
45,044
34,991
29,431
22,150
22,635
25,328
21,006
19,110
16,904
16,90419,11021,00625,32822,63522,15029,43134,99145,04452,11860,39457,52439,97924,9427,59912,25812,44817,68320,95737,01130,63528,4477,22811,8307,09575,83022,26914,0149,67610,8945,49645,0004,6370003,593
       Short-term Investments 
0
0
0
0
0
0
400
49,785
44,849
46,877
25,958
20,946
73,688
49,824
37,503
9,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000009,19237,50349,82473,68820,94625,95846,87744,84949,785400000000
       Net Receivables 
15,130
0
0
0
7,832
4,845
9,913
2,958
4,284
1,926
4,715
528
2,141
3,098
6,145
6,202
5,220
5,801
7,378
7,918
7,022
7,022
288
1,463
2,369
2,421
3,110
3,096
3,664
3,114
0
0
2,500
0
0
0
0
00002,500003,1143,6643,0963,1102,4212,3691,4632887,0227,0227,9187,3785,8015,2206,2026,1453,0982,1415284,7151,9264,2842,9589,9134,8457,83200015,130
       Inventory 
17,625
0
0
0
20,322
9,127
20,130
11,574
6,639
8,063
7,984
1,237
1,028
1,285
2,970
3,969
1,785
4,346
6,967
7,482
6,139
6,139
2,503
4,042
4,783
2,822
2,195
3,650
3,082
2,690
0
0
1,571
0
0
0
0
00001,571002,6903,0823,6502,1952,8224,7834,0422,5036,1396,1397,4826,9674,3461,7853,9692,9701,2851,0281,2377,9848,0636,63911,57420,1309,12720,32200017,625
       Other Current Assets 
5,203
0
0
0
2,343
5,435
4,308
4,218
5,966
6,516
6,267
16,781
6,710
6,630
7,138
6,990
4,142
3,561
3,170
1,491
160
1,224
98
206
133
83
66
9
780
877
768
658
744
1,582
764
649
2,162
2,1626497641,58274465876887778096683133206981,2241601,4913,1703,5614,1426,9907,1386,6306,71016,7816,2676,5165,9664,2184,3085,4352,3430005,203
   > Long-term Assets 
0
0
0
0
77,322
77,182
78,312
21,194
20,444
20,397
19,698
15,700
21,923
23,052
23,750
18,539
18,805
23,199
22,455
23,767
23,413
10,419
8,021
6,767
6,283
5,903
5,709
5,132
4,031
3,512
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,7766,0036,2326,4846,7657,0777,3993,5124,0315,1325,7095,9036,2836,7678,02110,41923,41323,76722,45523,19918,80518,53923,75023,05221,92315,70019,69820,39720,44421,19478,31277,18277,3220000
       Property Plant Equipment 
3,202
0
0
0
4,179
4,624
6,342
6,139
5,910
6,384
6,205
6,163
5,843
5,936
5,638
5,608
5,202
9,459
8,874
8,252
7,693
7,133
6,571
6,010
5,537
5,157
4,963
4,386
3,963
3,444
7,399
7,077
6,765
6,484
6,232
6,003
5,776
5,7766,0036,2326,4846,7657,0777,3993,4443,9634,3864,9635,1575,5376,0106,5717,1337,6938,2528,8749,4595,2025,6085,6385,9365,8436,1636,2056,3845,9106,1396,3424,6244,1790003,202
       Goodwill 
13,902
0
0
0
13,902
13,902
13,902
0
0
0
0
0
0
0
0
0
0
0
0
0
-830
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000-830000000000000013,90213,90213,90200013,902
       Intangible Assets 
75,218
0
0
0
59,241
58,656
58,068
15,055
14,534
14,013
13,493
6,287
6,080
5,873
5,665
5,458
5,250
5,043
4,835
4,628
5,250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000005,2504,6284,8355,0435,2505,4585,6655,8736,0806,28713,49314,01314,53415,05558,06858,65659,24100075,218
       Long-term Assets Other 
0
0
0
0
0
0
41,294
15,055
14,534
0
0
3,250
10,000
11,243
12,447
7,473
8,353
8,697
8,746
10,887
11,300
3,286
1,450
757
746
746
746
746
68
68
-7,399
-7,077
-6,765
-6,484
-6,232
0
0
00-6,232-6,484-6,765-7,077-7,39968687467467467467571,4503,28611,30010,8878,7468,6978,3537,47312,44711,24310,0003,2500014,53415,05541,294000000
> Total Liabilities 
25,363
0
0
0
23,838
22,743
20,962
36,873
41,292
36,307
35,471
40,712
34,972
31,848
33,967
34,934
37,088
41,711
39,928
40,811
41,566
10,092
9,859
35,218
36,953
58,249
57,593
56,713
55,385
51,068
15,752
15,933
16,241
11,713
12,659
12,411
12,621
12,62112,41112,65911,71316,24115,93315,75251,06855,38556,71357,59358,24936,95335,2189,85910,09241,56640,81139,92841,71137,08834,93433,96731,84834,97240,71235,47136,30741,29236,87320,96222,74323,83800025,363
   > Total Current Liabilities 
19,835
0
0
0
19,943
18,690
17,028
15,233
19,544
14,459
11,883
14,870
18,510
17,273
18,102
15,442
17,610
18,290
16,598
37,252
38,239
6,993
7,002
7,417
14,539
29,344
30,864
32,380
34,757
23,857
7,003
7,786
8,706
5,797
6,911
6,836
7,224
7,2246,8366,9115,7978,7067,7867,00323,85734,75732,38030,86429,34414,5397,4177,0026,99338,23937,25216,59818,29017,61015,44218,10217,27318,51014,87011,88314,45919,54415,23317,02818,69019,94300019,835
       Short-term Debt 
0
0
0
0
5,572
4,142
5,251
0
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
19,863
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
00002,0002,0002,0002,00011,66711,16710,66710,1675,0000019,86319,86319,70701,081004,1675,3333,33317,48418,74518,43518,38305,2514,1425,5720000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
18,383
18,435
18,745
17,484
3,333
5,333
4,167
0
0
1,081
0
19,707
19,863
0
0
0
5,000
10,167
10,667
11,167
11,667
2,000
2,000
2,000
2,000
0
0
0
0
00002,0002,0002,0002,00011,66711,16710,66710,1675,00000019,86319,70701,081004,1675,3333,33317,48418,74518,43518,38300000000
       Accounts payable 
11,472
0
0
0
10,084
12,197
11,192
12,380
15,498
11,271
8,293
11,327
11,976
7,263
9,535
9,808
11,671
11,043
11,904
12,073
13,043
5,001
4,662
3,911
5,583
5,352
5,196
3,687
3,462
3,910
3,269
3,243
3,499
4,134
4,873
4,000
3,984
3,9844,0004,8734,1343,4993,2433,2693,9103,4623,6875,1965,3525,5833,9114,6625,00113,04312,07311,90411,04311,6719,8089,5357,26311,97611,3278,29311,27115,49812,38011,19212,19710,08400011,472
       Other Current Liabilities 
8,363
0
0
0
6,016
4,375
5,442
14,593
18,733
13,581
10,439
14,870
15,177
4,677
4,400
5,634
5,939
7,247
4,694
5,472
5,333
1,992
2,340
7,417
9,539
13,825
20,197
21,213
23,090
16,907
1,734
2,543
6,706
1,663
2,038
2,836
3,240
3,2402,8362,0381,6636,7062,5431,73416,90723,09021,21320,19713,8259,5397,4172,3401,9925,3335,4724,6947,2475,9395,6344,4004,67715,17714,87010,43913,58118,73314,5935,4424,3756,0160008,363
   > Long-term Liabilities 
0
0
0
0
3,895
4,053
3,934
21,640
21,748
21,848
23,588
25,842
16,462
14,575
15,865
19,492
19,478
23,421
23,330
3,559
3,327
3,099
2,857
27,801
22,414
28,905
26,729
24,333
20,628
27,211
8,749
8,147
7,535
5,916
5,748
5,575
5,397
5,3975,5755,7485,9167,5358,1478,74927,21120,62824,33326,72928,90522,41427,8012,8573,0993,3273,55923,33023,42119,47819,49215,86514,57516,46225,84223,58821,84821,74821,6403,9344,0533,8950000
       Long term Debt Total 
0
0
0
0
0
0
0
18,111
18,383
18,435
18,745
17,484
15,728
13,975
15,400
19,143
19,278
19,415
19,558
0
0
0
0
25,199
0
4,614
4,323
0
0
0
0
0
0
0
0
0
0
00000000004,3234,614025,199000019,55819,41519,27819,14315,40013,97515,72817,48418,74518,43518,38318,1110000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-5,572
-4,142
-5,251
0
-18,383
-18,435
-18,745
-17,484
-3,333
-5,333
-4,167
0
0
2,914
3,759
-16,160
-16,536
-16,764
2,857
2,602
-2,640
-8,048
-8,798
-9,557
-10,326
-935
4,390
4,237
4,079
5,916
5,748
5,575
5,397
5,3975,5755,7485,9164,0794,2374,390-935-10,326-9,557-8,798-8,048-2,6402,6022,857-16,764-16,536-16,1603,7592,91400-4,167-5,333-3,333-17,484-18,745-18,435-18,3830-5,251-4,142-5,5720000
       Long-term Liabilities Other 
0
0
0
0
0
0
88
433
469
611
2,047
8,358
734
600
465
349
200
4,006
13
12
3,327
3,099
2,857
2,602
0
24,291
20,537
18,711
15,580
23,342
0
0
0
0
0
0
0
000000023,34215,58018,71120,53724,29102,6022,8573,0993,32712134,0062003494656007348,3582,04761146943388000000
       Deferred Long Term Liability 
0
0
0
0
19,135
0
3,846
3,096
2,896
2,802
2,796
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000002,7962,8022,8963,0963,846019,1350000
> Total Stockholder Equity
94,608
0
0
0
88,618
118,846
97,197
63,750
50,566
61,486
51,420
90,310
82,035
68,364
56,030
44,000
30,406
39,130
26,199
19,745
11,842
15,152
8,650
2,202
16,594
10,504
13,881
7,292
1,216
-5,884
23,047
15,762
17,974
23,256
16,253
14,718
12,221
12,22114,71816,25323,25617,97415,76223,047-5,8841,2167,29213,88110,50416,5942,2028,65015,15211,84219,74526,19939,13030,40644,00056,03068,36482,03590,31051,42061,48650,56663,75097,197118,84688,61800094,608
   Common Stock
267,279
0
0
0
320,606
20
0
20
20
21
21
21
22
22
23
23
23
45
45
45
45
45
45
45
46
46
47
47
47
47
47
47
48
49
49
56
61
615649494847474747474746464545454545454523232322222121212020020320,606000267,279
   Retained Earnings -223,447-217,545-211,211-203,263-206,036-201,394-193,750-221,760-214,063-207,791-200,794-192,862-185,606-178,553-171,762-164,959-167,856-159,682-152,758-139,426-127,408-113,279-100,717-87,573-73,719-63,958-101,826-90,637-80,692-65,746-257,716-244,878-231,988000-172,671
   Capital Surplus 
0
0
0
0
0
0
0
149,493
151,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
0
203,320
214,628
0
0
0
0
0
0
0
0
0
0
0000000000214,628203,3200180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143151,271149,4930000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
320,606
363,704
354,913
129,493
131,271
152,143
153,239
154,257
155,837
155,998
156,760
157,258
157,791
178,511
178,912
179,382
179,653
180,066
180,367
180,710
202,154
203,320
214,628
215,036
215,232
215,829
216,750
217,109
223,962
226,470
227,415
232,207
235,607
235,607232,207227,415226,470223,962217,109216,750215,829215,232215,036214,628203,320202,154180,710180,367180,066179,653179,382178,912178,511157,791157,258156,760155,998155,837154,257153,239152,143131,271129,493354,913363,704320,6060000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-567
Gross Profit-567-567
 
Operating Income (+$)
Gross Profit-567
Operating Expense-28,311
Operating Income-28,878-28,878
 
Operating Expense (+$)
Research Development16,540
Selling General Administrative11,771
Selling And Marketing Expenses0
Operating Expense28,31128,311
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-28,878
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,650-39,106
EBIT - interestExpense = -28,878
-18,650
-17,411
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-28,878-18,650
Earnings Before Interest and Taxes (EBITDA)-28,311
 
After tax Income (+$)
Income Before Tax-18,650
Tax Provision-0
Net Income From Continuing Ops-17,617-18,650
Net Income-17,411
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses28,878
Total Other Income/Expenses Net10,2280
 

Technical Analysis of Aptevo Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aptevo Therapeutics Inc. The general trend of Aptevo Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aptevo Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aptevo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.87 < 5.5 < 7.48.

The bearish price targets are: .

Tweet this
Aptevo Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aptevo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aptevo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aptevo Therapeutics Inc. The current macd is -1.12077466.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aptevo Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aptevo Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aptevo Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aptevo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAptevo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aptevo Therapeutics Inc. The current adx is 20.83.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aptevo Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Aptevo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aptevo Therapeutics Inc. The current sar is 1.09185789.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aptevo Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aptevo Therapeutics Inc. The current rsi is 21.74. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Aptevo Therapeutics Inc Daily Relative Strength Index (RSI) ChartAptevo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aptevo Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aptevo Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aptevo Therapeutics Inc Daily Stochastic Oscillator ChartAptevo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aptevo Therapeutics Inc. The current cci is -64.31254476.

Aptevo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAptevo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aptevo Therapeutics Inc. The current cmo is -66.60713984.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aptevo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAptevo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aptevo Therapeutics Inc. The current willr is -99.76190476.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Aptevo Therapeutics Inc Daily Williams %R ChartAptevo Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aptevo Therapeutics Inc. The current atr is 0.43777619.

Aptevo Therapeutics Inc Daily Average True Range (ATR) ChartAptevo Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aptevo Therapeutics Inc. The current obv is -3,417,099.

Aptevo Therapeutics Inc Daily On-Balance Volume (OBV) ChartAptevo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aptevo Therapeutics Inc. The current mfi is 23.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aptevo Therapeutics Inc Daily Money Flow Index (MFI) ChartAptevo Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aptevo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Aptevo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aptevo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.737
Ma 20Greater thanMa 502.077
Ma 50Greater thanMa 1004.225
Ma 100Greater thanMa 2005.854
OpenGreater thanClose0.680
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aptevo Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Aptevo Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aptevo Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aptevo Therapeutics Inc

I send you an email if I find something interesting about Aptevo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aptevo Therapeutics Inc.

Receive notifications about Aptevo Therapeutics Inc in your mailbox!